Suppr超能文献

冷冻制剂玻璃小瓶破裂的机理研究。II. 无定形蛋白质制剂导致的小瓶破裂

Mechanistic studies of glass vial breakage for frozen formulations. II. Vial breakage caused by amorphous protein formulations.

作者信息

Jiang Ge, Akers Mike, Jain Manish, Guo Jeremy, Distler Adrian, Swift Rob, Wadhwa Manpreet-Vick S, Jameel Feroz, Patro Sugu, Freund Erwin

机构信息

Drug Product and Device Development, Amgen Inc., USA.

出版信息

PDA J Pharm Sci Technol. 2007 Nov-Dec;61(6):452-60.

Abstract

In an accompanying article we have described parameters that influence vial breakage in freeze-thaw operations when using crystalizable mannitol formulations, and further provided a practical approach to minimize the breakage in manufacturing settings. Using two diagnostic tools-thermal mechanical analysis (TMA) and strain gage, we investigated the mechanism of mannitol vial breakage and concluded that the breakage is related to sudden volume expansions in the frozen plug due to crystallization events. Glass vial breakage has also been observed with a number of frozen protein formulations consisting of only amorphous ingredients. Therefore, in this study, we applied the methodologies and learnings from the prior investigation to further explore the mechanism of vial breakage during freeze-thaw of amorphous protein products. It was found that temperature is a critical factor, as breakage typically occurred when the products were frozen to -70 degrees C, while freezing only to -30 degrees C resulted in negligible breakage. When freezing to -70 degrees C, increased protein concentration and higher fill volume induced more vial breakage, and the breakage occurred mostly during freezing. In contrast to the previous findings for crystallizable formulations, an intermediate staging step at -30 degrees C did not reduce breakage for amorphous protein formulations, and even slightly increased the breakage rate. The TMA profiles revealed substantially higher thermal contraction of frozen protein formulations when freezing below -30 degrees C, as compared to glass. Such thermal contraction of frozen protein formulations caused inward deformation of glass and subsequent rapid movement of glass when the frozen plug separates from the vial. Increasing protein concentration caused more significant inward glass deformation, and therefore a higher level of potential energy was released during the separation between the glass and frozen formulation, causing higher breakage rates. The thermal expansion during thawing generated moderate positive strain on glass and explained the thaw breakage occasionally observed. The mechanism of vial breakage during freeze-thaw of amorphous protein formulations is different compared to crystallizable formulations, and accordingly requires different approaches to reduce vial breakage in manufacturing. Storing and shipping at no lower than -30 degrees C effectively prevents breakage of amorphous protein solutions. If lower temperature such as -70 degrees C is unavoidable, the risk of breakage can be reduced by lowering fill volume.

摘要

在一篇随附文章中,我们描述了使用可结晶甘露醇制剂时影响冻融操作中安瓿瓶破损的参数,并进一步提供了一种在生产环境中尽量减少破损的实用方法。使用热机械分析(TMA)和应变片这两种诊断工具,我们研究了甘露醇安瓿瓶破损的机制,并得出结论,破损与由于结晶事件导致的冷冻塞中体积的突然膨胀有关。在许多仅由无定形成分组成的冷冻蛋白质制剂中也观察到了玻璃安瓿瓶破损。因此,在本研究中,我们应用先前调查的方法和经验教训,进一步探索无定形蛋白质产品冻融过程中安瓿瓶破损的机制。研究发现温度是一个关键因素,因为破损通常发生在产品冷冻至-70℃时,而仅冷冻至-30℃时破损可忽略不计。当冷冻至-70℃时,蛋白质浓度增加和灌装体积增大导致更多的安瓿瓶破损,且破损大多发生在冷冻过程中。与之前关于可结晶制剂的研究结果相反,在-30℃的中间分级步骤并不能减少无定形蛋白质制剂的破损,甚至会略微提高破损率。TMA曲线显示,与玻璃相比,当冷冻至-30℃以下时,冷冻蛋白质制剂的热收缩明显更高。冷冻蛋白质制剂的这种热收缩导致玻璃向内变形,随后当冷冻塞与安瓿瓶分离时玻璃快速移动。蛋白质浓度增加导致玻璃向内变形更显著,因此在玻璃与冷冻制剂分离过程中释放出更高水平的势能,导致更高的破损率。解冻过程中的热膨胀在玻璃上产生适度的正应变,并解释了偶尔观察到的解冻破损现象。无定形蛋白质制剂冻融过程中安瓿瓶破损的机制与可结晶制剂不同,但相应地需要不同的方法来减少生产过程中的安瓿瓶破损。在不低于-30℃的温度下储存和运输可有效防止无定形蛋白质溶液的破损。如果不可避免要使用更低的温度,如-70℃,则可通过降低灌装体积来降低破损风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验